SG11202010821TA - Vaccine composition - Google Patents
Vaccine compositionInfo
- Publication number
- SG11202010821TA SG11202010821TA SG11202010821TA SG11202010821TA SG11202010821TA SG 11202010821T A SG11202010821T A SG 11202010821TA SG 11202010821T A SG11202010821T A SG 11202010821TA SG 11202010821T A SG11202010821T A SG 11202010821TA SG 11202010821T A SG11202010821T A SG 11202010821TA
- Authority
- SG
- Singapore
- Prior art keywords
- vaccine composition
- vaccine
- composition
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18523—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1807378.3A GB201807378D0 (en) | 2018-05-04 | 2018-05-04 | Vaccine composition |
| GBGB1807376.7A GB201807376D0 (en) | 2018-05-04 | 2018-05-04 | HMCV Vaccine Composition |
| PCT/GB2019/051245 WO2019211630A2 (en) | 2018-05-04 | 2019-05-03 | Vaccine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010821TA true SG11202010821TA (en) | 2020-11-27 |
Family
ID=66484095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010821TA SG11202010821TA (en) | 2018-05-04 | 2019-05-03 | Vaccine composition |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210128717A1 (en) |
| EP (1) | EP3787676A2 (en) |
| JP (1) | JP2021523937A (en) |
| KR (1) | KR20210013571A (en) |
| CN (1) | CN112638411A (en) |
| AU (1) | AU2019263706A1 (en) |
| BR (1) | BR112020022393A2 (en) |
| CA (1) | CA3099381A1 (en) |
| IL (1) | IL278418B2 (en) |
| SG (1) | SG11202010821TA (en) |
| WO (1) | WO2019211630A2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201917265D0 (en) * | 2019-11-27 | 2020-01-08 | Univ Sheffield | Bonded neurotoxins |
| CN114634578B (en) * | 2020-12-15 | 2024-04-02 | 榕森生物科技(北京)有限公司 | Vaccine compositions against novel coronavirus infections |
| CA3202379A1 (en) * | 2020-12-18 | 2022-06-23 | Adam Frederik Sander Bertelsen | Nucleic acid vaccines |
| WO2022234276A1 (en) * | 2021-05-04 | 2022-11-10 | SpyBiotech Limited | Adenoviral vectors and vaccines thereof |
| WO2023155318A1 (en) * | 2022-02-21 | 2023-08-24 | 悦康药业集团股份有限公司 | Method for optimizing virus membrane fusion inhibitor, broad-spectrum anti-coronavirus lipopeptide and use thereof |
| CN115920026B (en) * | 2022-04-02 | 2023-11-14 | 中山大学 | Heat-resistant multimeric protein scaffolds and use of heat-resistant multimeric protein scaffolds in vaccines |
| CN117462666A (en) * | 2022-09-30 | 2024-01-30 | 烟台派诺生物技术有限公司 | Immune composition product for preventing or treating varicella-zoster virus related diseases and preparation method thereof |
| CN117264081A (en) * | 2023-11-21 | 2023-12-22 | 华南理工大学 | Dipeptide receptor agonist and preparation method and application thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2222710B8 (en) | 2007-12-24 | 2016-10-12 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
| WO2011009877A1 (en) | 2009-07-24 | 2011-01-27 | Basf Se | Flameproofed polyamide molding compounds |
| GB201002362D0 (en) | 2010-02-11 | 2010-03-31 | Isis Innovation | Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds |
| DK2776567T3 (en) * | 2011-11-11 | 2021-04-26 | Variation Biotechnologies Inc | Compositions and methods of treatment of cytomegalovirus. |
| MX355469B (en) | 2012-07-06 | 2018-04-19 | Novartis Ag | Complexes of cytomegalovirus proteins. |
| US10017543B2 (en) | 2013-03-13 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| WO2015095811A2 (en) * | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| DE16703049T1 (en) * | 2015-01-15 | 2018-07-12 | University Of Copenhagen | VIRUSUAL PARTICLES WITH EFFICIENT EPITOPHONE |
| GB201509782D0 (en) | 2015-06-05 | 2015-07-22 | Isis Innovation | Methods and products for fusion protein synthesis |
| CN115960263A (en) * | 2016-03-29 | 2023-04-14 | 美国政府(由卫生和人类服务部的部长所代表) | Substitution-modified pre-fusion RSV F proteins and uses thereof |
| CN106081304A (en) | 2016-07-27 | 2016-11-09 | 佛山市高明金荣华乐金属制品有限公司 | A kind of novel foldable casing and assembly and disassembly methods thereof |
| GB201705750D0 (en) | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | Peptide ligase and use therof |
| GB201706430D0 (en) | 2017-04-24 | 2017-06-07 | Univ Oxford Innovation Ltd | Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof |
-
2019
- 2019-05-03 KR KR1020207034602A patent/KR20210013571A/en unknown
- 2019-05-03 WO PCT/GB2019/051245 patent/WO2019211630A2/en unknown
- 2019-05-03 CA CA3099381A patent/CA3099381A1/en active Pending
- 2019-05-03 JP JP2021510553A patent/JP2021523937A/en active Pending
- 2019-05-03 EP EP19723480.0A patent/EP3787676A2/en active Pending
- 2019-05-03 IL IL278418A patent/IL278418B2/en unknown
- 2019-05-03 BR BR112020022393-0A patent/BR112020022393A2/en unknown
- 2019-05-03 SG SG11202010821TA patent/SG11202010821TA/en unknown
- 2019-05-03 AU AU2019263706A patent/AU2019263706A1/en active Pending
- 2019-05-03 CN CN201980044956.2A patent/CN112638411A/en active Pending
- 2019-05-03 US US17/052,707 patent/US20210128717A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019263706A1 (en) | 2020-11-19 |
| CN112638411A (en) | 2021-04-09 |
| CA3099381A1 (en) | 2019-11-07 |
| BR112020022393A2 (en) | 2021-02-02 |
| KR20210013571A (en) | 2021-02-04 |
| WO2019211630A3 (en) | 2019-12-05 |
| US20210128717A1 (en) | 2021-05-06 |
| WO2019211630A2 (en) | 2019-11-07 |
| IL278418B1 (en) | 2023-09-01 |
| EP3787676A2 (en) | 2021-03-10 |
| IL278418A (en) | 2020-12-31 |
| IL278418B2 (en) | 2024-01-01 |
| JP2021523937A (en) | 2021-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202010821TA (en) | Vaccine composition | |
| GB201802339D0 (en) | Immunogenic composition | |
| GB201711635D0 (en) | Immunogenic composition | |
| GB201811100D0 (en) | Composition | |
| GB201810492D0 (en) | Composition | |
| GB201711637D0 (en) | Immunogenic composition | |
| GB201812145D0 (en) | Composition | |
| GB201804434D0 (en) | Composition | |
| GB201910794D0 (en) | Vaccine | |
| IL282753A (en) | Immunogenic composition | |
| GB2562241B (en) | Vaccine compositions | |
| SG11202009147UA (en) | Vaccine compositions | |
| GB201818827D0 (en) | Composition | |
| GB201815031D0 (en) | Composition | |
| GB201703529D0 (en) | Vaccine composition | |
| GB201811382D0 (en) | Vaccine | |
| GB201803692D0 (en) | Immunogenic composition | |
| GB201819861D0 (en) | Composition | |
| EP3677276A4 (en) | Vaccine composition | |
| GB201815032D0 (en) | Composition | |
| GB201718251D0 (en) | Vaccine Compositions | |
| GB201809123D0 (en) | Composition | |
| GB201801596D0 (en) | Composition | |
| GB201807378D0 (en) | Vaccine composition | |
| GB201807376D0 (en) | HMCV Vaccine Composition |